Part D Starts Slow
This article was originally published in RPM Report
Executive Summary
The new Medicare drug benefit generated plenty of controversy in its first weeks, but the start-up glitches have very little to do with the long term outlook for the program. One key factor matters for 2006: enrollment. And with just 3.6 million voluntary sign-ups so far, Part D is not off to a fast start.
You may also be interested in...
Unapproved Drugs Become Unpaid Drugs, Effective January 1
Pharmacies and wholesalers are expressing their concern about the potential for an upcoming policy change in Part D to disrupt dispensing. Beginning Jan. 1, any medication that does not have an NDC registered with FDA will no longer be covered by the drug benefit.
MedPAC On Steroids: The Implications of a New Medicare Advisory Council
The creation of an independent health council to weigh in on Medicare reimbursement rates may be part of a final health reform bill. The idea has a number of implications for biopharma-good and bad.
Tilting the Contracting Scales: Part D Plans Have Advantages Over Manufacturers in 2008
Contracting between pharma companies and Part D plan sponsors that took place last year for 2007 pricing and formulary placement was a relatively straightforward process. This year will be more interesting.